Welcome to our dedicated page for IGM Biosciences news (Ticker: $IGMS), a resource for investors and traders seeking the latest updates and insights on IGM Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IGM Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IGM Biosciences's position in the market.
IGM Biosciences, Inc. (Nasdaq: IGMS) exceeded enrollment targets in clinical trials for aplitabart in colorectal cancer and imvotamab in rheumatoid arthritis. Financially, the company reported $293.8 million in cash and investments, with net loss of $49.8 million for the first quarter of 2024. The company expects full year 2024 GAAP operating expenses of $210-220 million and collaboration revenue of $63 million.
IGM Biosciences, Inc. (Nasdaq: IGMS) will be participating in a fireside chat at the 2024 RBCCM Global Healthcare Conference on May 14, 2024. The event will be webcasted live and available for replay on the company's website for 90 days.